Cart
sales@molnova.com
Amonafide
CAS No. 69408-81-7
Amonafide( AS1413 )
Catalog No. M15655 CAS No. 69408-81-7
A novel topoisomerase II (Topo II) inhibitor and DNA intercalator that induces apoptotic signaling by blocking the binding of Topo II to DNA.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100mg | 382 | In stock |
|
| 50mg | 228 | In stock |
|
| 10mg | 68 | In stock |
|
Biological Information
-
Product NameAmonafide
-
NoteResearch use only, not for human use.
-
Brief DescriptionA novel topoisomerase II (Topo II) inhibitor and DNA intercalator that induces apoptotic signaling by blocking the binding of Topo II to DNA.
-
DescriptionA novel topoisomerase II (Topo II) inhibitor and DNA intercalator that induces apoptotic signaling by blocking the binding of Topo II to DNA.Chemotherapeutic Agents Phase 3 Discontinued
-
SynonymsAS1413
-
PathwayCell Cycle/DNA Damage
-
TargetTopoisomerase
-
RecptorTopoII
-
Research AreaCancer
-
IndicationChemotherapeutic
Chemical Information
-
CAS Number69408-81-7
-
Formula Weight283.33
-
Molecular FormulaC16H17N3O2
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C1N(CCN(C)C)C(C2=CC(N)=CC3=CC=CC1=C23)=O
-
Chemical Name1H-Benz[de]isoquinoline-1,3(2H)-dione, 5-amino-2-[2-(dimethylamino)ethyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Allen SL, et al. Expert Opin Investig Drugs. 2011 Jul;20(7):995-1003.
2. Zhu H, et al. Mol Cancer Ther. 2007 Feb;6(2):484-95.
3. Liang X, et al. Mol Cancer Res. 2010 Dec;8(12):1619-32.
2. Zhu H, et al. Mol Cancer Ther. 2007 Feb;6(2):484-95.
3. Liang X, et al. Mol Cancer Res. 2010 Dec;8(12):1619-32.
molnova catalog
related products
-
Nalidixic acid sodiu...
A synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum.
-
Amenamevir
Amenamevir is a novel helicase-primase inhibitor that is active against varicella-zoster virus and herpes simplex virus types 1 and 2 (EC50: 14 ng/mL).
-
SN-38
LE-SN38 is NeoPharm’s NeoLipid liposomal formulation of SN-38, the active metabolite of irinotecan (Camptosar), a chemotherapeutic pro-drug approved for the treatment of advanced colorectal Y.
